IPP Bureau
Zydus receives EIR with VAI from USFDA for Moraiya facility
By IPP Bureau - November 08, 2022
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%
By IPP Bureau - November 07, 2022
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe
By IPP Bureau - November 07, 2022
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
By IPP Bureau - November 07, 2022
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Lupin receives tentative approval from USFDA for Drospirenone Tablets
By IPP Bureau - November 07, 2022
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression
By IPP Bureau - November 07, 2022
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
By IPP Bureau - November 07, 2022
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Zydus Announces New Data Presentations at The Liver Meeting 2022
By IPP Bureau - November 04, 2022
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr
By IPP Bureau - November 04, 2022
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
Hester Biosciences Q2 FY23 consolidated profit up at Rs. 6.94 Cr
By IPP Bureau - November 04, 2022
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
Sanofi India posts Q3CY22 net profit at Rs. 130.9 Cr
By IPP Bureau - November 04, 2022
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
Alembic receives USFDA approval for Ketorolac Tromethamine Injection
By IPP Bureau - November 04, 2022
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Alembic receives USFDA approval for Mesalamine ER Capsules
By IPP Bureau - November 03, 2022
Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults.
Glenmark receives ANDA approval for Sodium Phenylbutyrate Tablets
By IPP Bureau - November 03, 2022
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
SRL Diagnostics inaugurates an upgraded laboratory at Gurugram
By IPP Bureau - November 03, 2022
The laboratory is equipped to perform high-volume diagnostic testing services
